Universal Health Services, Inc. (UHS) Q3 Rev +5.3% to $4.73B; EPS $5.22, Down YoY

Universal Health Services, Inc. (UHS) reported Q3 2026 revenue of $4.733B, up 5.3% YoY, and EPS of $5.22, down from $5.86 in Q3 2025. Adjusted EBITDA net of NCI was $624.6M, down from $670.6M. The company noted steady revenue growth but softer margins.

Original reporting
Published Oct 27, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Universal Health Services, Inc. (UHS) Q3 Rev +5.3% to $4.73B; EPS $5.22, Down YoY — source image
Decision brief

The 30-second read

$UHSBearishMed
01

Why it matters

The earnings miss on EPS may trigger a sell-off, while revenue growth offers a modest upside narrative.

02

Market read

UHS earnings provide fresh data for healthcare sector investors and may affect related stocks.

03

What to watch

Potential insurance recoveries and liability settlements could improve future margins if realized.

Relevance 8/10Novelty 8/10Timing: post-market

Background

Universal Health Services released its Q3 2026 earnings, showing modest revenue growth but weaker profitability.

Company-level read

Ticker impact

$UHSBearishHigh confidence
Context

UHS reported Q3 2026 revenue of $4.733B (+5.3% YoY) and EPS $5.22, marking the first public disclosure of its quarterly results.

Expected impact

likely downside as investors price in softer margins and lower EPS versus prior year.

Evidence & confidence

The earnings release is fresh information; EPS miss and margin decline are typical bearish catalysts.

Market effects

UHS results may influence the broader healthcare services sector, highlighting margin pressure trends.

UHS is a U.S. healthcare provider; impact is primarily on U.S. markets.

Limited global relevance beyond U.S. healthcare investors.

Counterpoint

Despite EPS miss, revenue growth could support a short-term rally if investors focus on top-line strength.

Key entities

  • Universal Health Services, Inc.

    U.S.-based provider of acute care and behavioral health services.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.